Objectives: Ridinilazole (SMT19969) is a narrow-spectrum, non-absorbable antimicrobial with activity against Clostridium difficile undergoing clinical trials. The purpose of this study was to assess the pharmacological activity of ridinilazole and assess the effects on cell morphology.
Introduction
According to the US CDC, the annual incidence of Clostridium difficile infection (CDI) exceeds 500 000 hospitalized cases with 29 000 deaths. 1, 2 Treatment options for CDI are limited to metronidazole, fidaxomicin and oral vancomycin. 3, 4 Morbidity and mortality, including the recurrence of CDI, continues to be a major concern with recurrence rates up to 25% after discontinuation of treatment in patients given metronidazole or vancomycin. 5, 6 Moreover, patients with at least one recurrence have a higher probability of experiencing further recurrences. 7 In addition to the significant morbidity and mortality, CDI increases healthcare costs due to extended hospitalizations and re-hospitalizations. 8, 9 The pathogenesis of CDI involves secretion of active toxins (A and B) by C. difficile with host inflammatory response to these toxins playing a vital role in disease progression. IL-8 and other cytokines directly contribute to the proinflammatory response. 10 -12 Although C. difficile is largely confined to the colon, CDI is typically associated with a systemic inflammatory reaction marked by leucocytosis that is, in part, thought to be mediated by toxins A and B disseminating systemically from the gastrointestinal tract. 13, 14 Ridinilazole is a novel, non-absorbable narrow-spectrum antibiotic that is currently in clinical development for the treatment of CDI. 15 -17 Ridinilazole has been shown to have potent activity against multiple strains of C. difficile and has demonstrated efficacy in both in vitro gut and in vivo hamster models. and associated changes in the inflammatory response. The purpose of this study was to assess the pharmacological activity of ridinilazole and determine the morphological effects of ridinilazole on C. difficile.
Materials and methods

Compounds, bacterial strains and growth media
Ridinilazole was provided by Summit Therapeutics and re-suspended in DMSO (Sigma-Aldrich). C. difficile strain R20291 (BI/027/NAP1) was used for all the experiments. All cultures were grown in a vinyl anaerobic chamber (Coy Lab Products) at 378C. Liquid microbiological cultures were grown in brain-heart infusion (BHI) medium (Hardy Diagnostics) supplemented with 0.1% sodium taurocholate (Alfa Aesar) during time-kill experiments. For colony recovery and counts, bacteria were grown on blood agar plates (Hardy Diagnostics). Metronidazole and vancomycin were purchased from commercial suppliers (Sigma-Aldrich). Caco-2 human gut epithelial cells were grown in Eagle's minimal essential medium (EMEM; ATCC 302003) for measurements of IL-8 release.
Kill kinetics
MICs of ridinilazole, metronidazole and vancomycin were determined for strain R20291 by broth microdilution in 0.1% sodium taurocholate BHI medium. Supra-MICs were used to mimic physiological concentrations and sub-MICs to assess the array of efficiency and efficacy of the drug. For experiments, cultures of C. difficile strain R20291 were prepared by inoculating one isolated colony on blood agar plate into BHI medium. After 24 h incubation at 378C in an anaerobic chamber, cultures were diluted 1:100 to 10 6 cfu/mL in fresh BHI medium supplemented with 0.1% sodium taurocholate and the appropriate concentration of antibiotic (0 h). Total viable counts were determined at 0, 24, 48 and 72 h of antibiotic treatment. One mL of culture was supplemented with 100 mL of killed yeast solution and centrifuged for 1 min at 10 000 rpm. 22 The supernatant was removed and the pellet resuspended in fresh BHI medium. Aliquots (100 mL) of sample serial dilutions were spread onto blood agar plates in duplicate and incubated at 378C in an anaerobic chamber for 48 h prior to colony counting. Spore viability was determined at 0 and 24 h. Total samples were centrifuged at 10000 rpm for 1 min and re-suspended in 100 mL of isopropanol to kill vegetative cells. Spore samples were then diluted and 100 mL was spread onto blood agar plates in duplicate and incubated for 48 h at 378C in an anaerobic chamber prior to colony counting. The limit of detection for these assays was 500 cfu/mL.
Sample preparation for microscopy
Five mL of each sample from time-kill studies was centrifuged for 5 min at 5000 rpm. The pellets were resuspended in 200 mL of 4% paraformaldehyde and incubated for 1 h at room temperature. The samples were centrifuged again for 1 min at 10 000 rpm, resuspended in 50 mL of H 2 O and stored at 48C prior to microscopy experiments.
Scanning electron microscopy
Samples were incubated for 30 min on poly-L-lysine-coated coverslips and allowed to dry. Twenty nanometres of gold was applied to the sample for coating using a Denton Desk II Sputtering System (Denton Vacuum). Coverslips were transferred to a FEI XL-30FEG scanning electron microscope (FEI). Working distance was set to 5 mm and high-resolution mode was used to image the cells. Images were taken at 15.0 kV at designated magnifications. After acquiring the images, the image files were opened in FIJI (http://fiji.sc/Welcome). Scale bars were calibrated and cell length was determined using the multi-measure function.
Confocal microscopy
The cells were stained for 1 h with 500 mg/mL FM4-64 (Life Technologies) in DMSO. Cells were washed twice with PBS and then re-diluted in PBS before being mounted on slides in mounting medium containing DAPI (Vector Labs). The slides were then transferred to a laser-scanning confocal microscope (LEICA TCS SP8) and images were taken using 405 nm and 560 nm lasers and a ×63 objective lens. Images files were opened in FIJI (http://fiji. sc/Welcome) and analysed using the cell counter function.
Toxin A and B concentration
Toxin A and B levels were measured by a commercially available ELISA with the C. difficile Toxin A or B quanti kit (tgcBIOMICS), according to the manufacturer's instructions. Limit of detection for toxin A or B levels was 0.31 ng/mL. Bassères et al.
Eukaryotic cell culture
Caco-2 cells (ATCC) were maintained and propagated in EMEM with 10% FBS (Hyclone), 100 U/mL penicillin G and 100 mg of streptomycin (Life Technologies) at 378C and in 5% CO 2 , according to the cell line supplier's instruction manual. All assays were carried out between cell passage numbers 5 and 15. In a 24-well plate, the cells were seeded and allowed to grow for 2 weeks to reach 95% confluence in the presence of complete medium to become two-dimensionally polarized before adding toxin. Medium was changed every other day with 20% FBS complete medium during the two-dimensional cell polarization event.
Inflammatory response determination
From the time-kill experiments, supernatants were collected and filtered at the indicated timepoints. Caco-2 cells were washed twice with PBS and 600 mL of EMEM was used as medium before adding 300 mL of filtered supernatant in duplicate. After a 24 h co-incubation, the supernatants from the Caco-2 cells were harvested and IL-8 release was quantified via a commercially available IL-8 ELISA kit (ThermoFisher Scientific), according to the manufacturer's instructions. The limit of detection for IL-8 levels was 5 pg/mL.
Experimental set-up and statistical analyses
For all sub-MIC experiments, the study drug was added at the same time as the initial inoculation of the one isolated colony on blood agar plate into BHI medium. The antibiotic and strain were then co-incubated for the next 24 h during an overnight culture prior to initial cfu counts and other experiments. For all supra-MIC experiments, the study drug was added after an Ridinilazole and C. difficile 1247 JAC overnight culture was grown in the absence of antibiotics. Statistical analysis was performed using SPSS statistics software, version 22 (IBM). Data are expressed as the mean+SEM. Data were assessed for significance using a Student's t-test or one-way ANOVA as appropriate. P, 0.05 was considered significant.
Results
Killing kinetics
For the C. difficile strain R20291 the MIC of ridinilazole was 0.06 mg/L, the MIC of metronidazole was 0.48 mg/L and the MIC of vancomycin was 0.96 mg/L. Supra-MIC killing kinetics showed that ridinilazole had a bactericidal effect at 4× and 40× MIC with a ≥3 log 10 reduction in cfu compared with control by 24 h (Figure 1a) . No recovery of growth was observed at 48 and 72 h post-inoculation. Spore recovery was also quantified at 0 and 24 h post-infection at supra-MIC concentrations and were found present in ,1% of the total population in all conditions at the start of the experiment (0 h) with no changes observed in control experiments at 24 h. Although the proportion of spores increased (Figure 1b) , the absolute number of spores remained constant (data not shown) indicating that ridinilazole did not induce sporulation of C. difficile.
Toxin production and IL-8 release
The effect of ridinilazole on the production of toxins A and B after 24 h of exposure is shown in Figure 2 . Toxins A and B were both present in all control experiments. Toxin B was not detected at any concentration of ridinilazole, including sub-MIC concentrations (0.125×20.5× MIC) during the first 24 h of growth (2D100%; P, 0.001). Toxin A concentrations were reduced 80% -90% (P,0.01) compared with control at all sub-MIC concentrations (Figure 2a) . In supra-MIC experiments, adding ridinilazole at 4× or 40× MIC after 24 h of growth reduced toxin A and B by 75% to .90% at 24, 48 and 72 h compared with control (P,0.05 for each; Figure 2b and c).
Caco-2 cells were exposed to C. difficile culture supernatants following sub-MIC exposure to ridinilazole for 24 h. Following 24 h of exposure to ridinilazole at 0.5× MIC, a 74% reduction in IL-8 release compared with drug-free controls was observed (P, 0.05). At 0.125× MIC and 0.25× MIC IL-8 reductions of 55% and 25% were recorded, respectively (Figure 3a and b) .
Comparison of results with metronidazole and vancomycin
The effect of exposure to ridinilazole, vancomycin and metronidazole at 0.5× MIC on cfu change (Figure 4a Bassères et al.
effect on toxin A or B concentrations, whereas ridinilazole demonstrated significant efficacy (Figure 4b ). In addition, IL-8 concentrations from Caco-2 cells exposed to vancomycin or metronidazole were similar to that of control (Figure 4c ).
Cell morphology
At supra-MIC concentrations, the cell morphology was severely perturbed after 24 h of treatment ( Figure 5 ). Most of the cells were destroyed (Figure 5c ) or forming aggregates (Figure 5d ) compared with control cells (Figure 5a and b) . At sub-MIC concentrations, a dose-dependent effect on cell length occurred at 24 h of treatment from 0.25× MIC and higher (Figure 6a ). Scanning electron microscopy images demonstrate an effect on cell length from 0.125× MIC that was even more dramatic at 0.25× and 0.5× MIC (Figure 6b ). Cell length ranged from 4 mm in control (lefthand panel of Figure 6b ) to 100 mm at 0.5× MIC (right-hand panel of Figure 6b ). Cell lengthening was quantified and shown in Figure 6 (c). A significant increase in cell length was observed from 0.25× MIC (P, 0.05), from 7 mm on average for control to 9 mm at 0.25× MIC and 20 mm at 0.5× MIC (P, 0.001). These results were statistically significant despite the heterogeneity in size (from 1 to 100 mm at 0.5× MIC). This could be due to the presence of cell debris from killed cells at 0.5× MIC. To characterize this cell-lengthening phenotype further, bacterial DNA and the cell wall were stained and visualized on a confocal microscope (Figure 7a ). While control cells displayed DNA division and septum formation (upper panels), DNA from treated cells was dividing, yet there was no septum formation (lower panels). This absence was observed starting at 0.125× MIC with a greater effect noted at 0.5× MIC (Figure 7b ). Cumulatively, these results suggest that ridinilazole may alter C. difficile cell division or proliferation.
Discussion
C. difficile is a spore-forming, Gram-positive, anaerobic organism that is transmitted from person-to-person via the oral -faecal route. 23 Progression to CDI most commonly involves release of toxins A and B by the vegetative cells of C. difficile eliciting a host inflammatory response that damages the colonic epithelial lining leading to diarrhoea, formation of pseudomembranes and systemic complications. 24 Colitis induced by C. difficile is characterized by a massive influx of neutrophils into the colonic mucosa. The movement of these neutrophils into the site of injury is believed to be a crucial event during the inflammatory process mediated primarily by IL-8 release by the colonocytes. 25, 26 In this study, we investigated the pharmacological properties of a novel, narrow-spectrum agent targeting C. difficile, ridinilazole. 
Ridinilazole and C. difficile
Novel findings from this study include the discovery of a marked decrease in toxins A and B production in C. difficile isolates exposed to sub-MIC concentrations of ridinilazole leading to decreased IL-8 production in cell lines exposed to ridinilazoletreated C. difficile isolates. The other novel finding on assessment of cell morphology following exposure to ridinilazole was that cell division was halted and an absence of septum formation, which may be a direct effect of, or a downstream response to, ridinilazole. Lastly, the potent bactericidal effect of this drug was demonstrated and confirmed results from previous studies. 18 In this study, toxins A and B concentrations were significantly decreased in C. difficile strains grown in the presence of sub-MIC concentrations of ridinilazole. Toxin concentrations also decreased significantly in C. difficile strains exposed to supra-MIC concentrations during 24 h. As toxins trigger the inflammatory response (mainly IL-8), 27 ridinilazole-exposed isolates were less bioactive as demonstrated by decreased IL-8 concentrations on exposed cell lines. Collectively, these data provide evidence that ridinilazole has bactericidal properties that reduces toxin levels and decreases the host inflammatory response during C. difficile infection. Previous studies have shown that fidaxomicin also inhibits toxin production at sub-MIC concentrations and a comparison of these two agents in the future will be necessary. 28 To the best of our knowledge, this is the first paper demonstrating morphological changes upon exposure of ridinilazole to C. difficile isolates. Using scanning electron microscopy and confocal microscopy, we showed significant cell lengthening in ridinilazole-exposed isolates that was associated with decreased septum formation. A study by Ransom et al. 29 identified and characterized midcell localizing division proteins or MLD proteins as essential for C. difficile cell division. Using mldABC and mldAB overexpressed mutants, C. difficile cells were shown to divide improperly and demonstrated a phenotype similar to what was observed in our ridinilazole-exposed isolates. Whether ridinilazole affects these particular cell division proteins or other proteins involved in the cell division pathway will require further study.
It is unclear the exact mechanisms for the toxin and antiinflammatory effects observed in this study; to determine if this is a direct or indirect effect mediated by membrane modification or cell division defects will also require further analysis. Likewise, we used a current epidemic 027 strain for these studies. Confirmation of these effects in other strains will be required. Finally, clinical applications taking advantage of these beneficial pharmacological effects will require more thorough investigation.
In conclusion, this study confirmed the bactericidal activities of ridinilazole and discovered decreased toxin A and B concentrations in C. difficile strains exposed to ridinilazole, associated with decreased bioactivity and IL-8 concentrations. This antiinflammatory effect may be important to resolve the main symptoms of CDI. While the mechanism of action of ridinilazole remains to be fully determined, it is apparent that this antibiotic has a promising future for the treatment of CDI.
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